Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
DMAC · Why this verdict
Why DiaMedica Therapeutics (DMAC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality score of 1.5 sits below the engine's 4.0 floor, and the engine flags 2 of 5 value-trap signals, margin compression at an operating margin of -69.1% and high leverage at a debt-to-equity ratio of 1.6, triggering an exit action note. Quality breakdown | Quality score should rise above the 4.0 floor and operating margin should improve from -69.1% over the next 12 months if the company approaches commercial viability. | →Stable |
| CounterPre-commercial biotechs routinely run deeply negative operating margins and elevated leverage while funding clinical trials, so these value-trap flags may not indicate the same distress they would for an operating company with revenue. | ||
The V9 asymmetry gate passed strongly at 4.86 against a 1.5 threshold, driven by 72.9% modeled upside versus 15% downside, with the analyst price target of $13.17 implying 103% upside from the current $7.62 price. Reward-to-risk math | Asymmetry ratio should remain elevated above 2 and modeled upside should stay well above 30% over the next 12 months if the analyst-target-driven setup holds. | →Stable |
| CounterAnalyst coverage is explicitly flagged as light, dampening the signal, so a small number of analysts' price target may not be reliable for a clinical-stage biotech whose value hinges on binary trial or regulatory outcomes. | ||
Momentum score is strong at 7.0, driven by an overbought RSI of 86, rising on-balance volume, and price above the 200-day moving average. Momentum breakdown | Momentum score should remain elevated above 6 and price should hold above the 200-day moving average over the next 12 months if the strength persists. | →Stable |
| CounterAn RSI of 86 is an extreme overbought reading, often seen ahead of binary biotech catalysts, and could reverse sharply on any negative trial or regulatory news given the stock's small-cap volatility profile. | ||
Key risks flag high short interest of 13% alongside a debt-to-equity risk component of 8.2, reflecting the market's skepticism about the balance sheet. Key risks | Short interest should decline from the current 13% level and the debt-to-equity risk component should improve over the next 12 months if financing risk eases. | →Stable |
| CounterHigh short interest in a speculative biotech with strong recent momentum and a large asymmetric upside setup can also fuel a short squeeze around binary catalysts rather than confirming further downside. | ||
Catalyst notes flag earnings concerns with only 1 beat against 2 misses in recent quarters, and an earnings-history score of just 1.1. Catalyst breakdown | The earnings beat rate should improve toward 50% or better over the next four quarters if execution stabilizes. | →Stable |
| CounterFor a pre-revenue clinical-stage biotech, quarterly EPS surprises versus tiny loss estimates are a weak proxy for the company's real value driver, which is trial data and regulatory progress rather than earnings beats. | ||
Quality score of 1.5 sits below the engine's 4.0 floor, and the engine flags 2 of 5 value-trap signals, margin compression at an operating margin of -69.1% and high leverage at a debt-to-equity ratio of 1.6, triggering an exit action note.
→StableQuality breakdown
- Expectation
- Quality score should rise above the 4.0 floor and operating margin should improve from -69.1% over the next 12 months if the company approaches commercial viability.
CounterPre-commercial biotechs routinely run deeply negative operating margins and elevated leverage while funding clinical trials, so these value-trap flags may not indicate the same distress they would for an operating company with revenue.
The V9 asymmetry gate passed strongly at 4.86 against a 1.5 threshold, driven by 72.9% modeled upside versus 15% downside, with the analyst price target of $13.17 implying 103% upside from the current $7.62 price.
→StableReward-to-risk math
- Expectation
- Asymmetry ratio should remain elevated above 2 and modeled upside should stay well above 30% over the next 12 months if the analyst-target-driven setup holds.
CounterAnalyst coverage is explicitly flagged as light, dampening the signal, so a small number of analysts' price target may not be reliable for a clinical-stage biotech whose value hinges on binary trial or regulatory outcomes.
Momentum score is strong at 7.0, driven by an overbought RSI of 86, rising on-balance volume, and price above the 200-day moving average.
→StableMomentum breakdown
- Expectation
- Momentum score should remain elevated above 6 and price should hold above the 200-day moving average over the next 12 months if the strength persists.
CounterAn RSI of 86 is an extreme overbought reading, often seen ahead of binary biotech catalysts, and could reverse sharply on any negative trial or regulatory news given the stock's small-cap volatility profile.
Key risks flag high short interest of 13% alongside a debt-to-equity risk component of 8.2, reflecting the market's skepticism about the balance sheet.
→StableKey risks
- Expectation
- Short interest should decline from the current 13% level and the debt-to-equity risk component should improve over the next 12 months if financing risk eases.
CounterHigh short interest in a speculative biotech with strong recent momentum and a large asymmetric upside setup can also fuel a short squeeze around binary catalysts rather than confirming further downside.
Catalyst notes flag earnings concerns with only 1 beat against 2 misses in recent quarters, and an earnings-history score of just 1.1.
→StableCatalyst breakdown
- Expectation
- The earnings beat rate should improve toward 50% or better over the next four quarters if execution stabilizes.
CounterFor a pre-revenue clinical-stage biotech, quarterly EPS surprises versus tiny loss estimates are a weak proxy for the company's real value driver, which is trial data and regulatory progress rather than earnings beats.
TrendMatrix Research · core thesis
Engine thesis — one sentence
DiaMedica Therapeutics shows a strongly asymmetric analyst-target setup and hot momentum, but a quality score deep below the engine's floor, cash-burn value-trap signals, and light analyst coverage warrant caution typical of a speculative clinical-stage biotech.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.6 |
- ▸Overbought (RSI 86)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.1 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 95%
Insider
5.9/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 6.8 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.5 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.0 |
| support resistance | 1.7 |
| 52w position | 5.3 |
| gap | 6.0 |
Risk (lower is worse)
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.3 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 2.2 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 7.2 |
| debt equity | 10.0 |
- ▸Elevated put/call: 1.67
- ▸High IV: 159%
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 2.7 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:7.3>=5.5
- ASYMMETRY:4.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
4.37
Upside
+65.5%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.5, and Momentum at 7.3; the weakest are Quality at 1.6, Catalyst at 3.5, and Technical at 3.5. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 4.37 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Asymmetry Analyst Upside
Trip ifAsymmetry ratio falls below 2.0, down from the current 4.86, or modeled upside falls below 30% (from 72.9%).
- P2Quality Below Floor Cash Burn Value Trap
Trip ifQuality score rises above 4.0, up from the current 1.5, or operating margin improves above -30% (from -69.1%).
- P3Overbought Momentum Above 200ma
Trip ifMomentum score falls below 5.0, down from the current 7.0, or price closes below its 200-day moving average.
- P4High Short Interest Elevated Leverage
Trip ifShort interest falls below 7%, down from the current 13%, or the debt-to-equity risk component falls below 5.0 (from 8.2).
- P5Mixed Earnings History Concerns
Trip ifEarnings beat rate rises to 3 of the next 4 quarters, or earnings-history score rises above 5.0 (from 1.1).